Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally (IN) as a potential cancer therapy. In this study, a 40-year-old woman with a grade 4 astrocytoma underwent standard surgery and chemotherapy but experienced tumor […]
This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers that originate from the metastatic spread of peripheral cancers, such as those of the lung, skin, breast, kidneys, and gastrointestinal tract are about 10-fold more […]
In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100 formulation for treating CNS disease in the brain. Malignancies of the CNS are difficult to treat because the blood-brain barrier (BBB) prevents most therapeutics from […]
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview of the existing issue with clinicians to try and find better ways to get pharma-therapeutics past the Blood-Brain Barrier (BBB) for patients struggling with CNS-based […]
In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed the definitive presence of NEO100 which is the first in-human clinical evidence of the viability of NEO100 intranasal delivery as a delivery mechanism for chemotherapeutic […]
The efficacy of human epidermal growth factor receptor 2-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability of the blood-brain barrier (BBB).NeOnc conducted an in vitro and in vivo study to look at the ability of NEO100 to assist in delivering trastuzumab […]
A Phase 1 Human Trial of NEO100 was conducted to study the therapeutics’ survivability impact and tolerance capacity. NEO100, which is NeOnc Technology Holdings’ core formulation of highly purified Peryllil Alcohol (POH), has been shown to be a highly effective transport mechanism for delivering therapeutics to the brain for the treatment of diseases such as brain-based glioblastomas. […]
A new study conducted by NeOnc into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August 2020. This study was done to specifically study not only the ability to permeate the BBB but also the impact such migration would have on the […]
NeOnc Technologies Holdings conducted a study of its NEO100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion assays. Ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan’s blue, methotrexate, checkpoint-inhibitory antibodies, or CAR T-cells was conducted on mouse models. The […]
A study showed that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutic delivery to the brain of a pharmaceutical agent that otherwise does not efficiently cross the BBB. One such agent is bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma. Preclinical studies established that BZM can be effective […]
